{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:29Z","timestamp":1787020829671,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003785","name":"Medical Scientific Research Foundation of Guangdong Province of China","doi-asserted-by":"crossref","award":["A2016013"],"award-info":[{"award-number":["A2016013"]}],"id":[{"id":"10.13039\/501100003785","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970176"],"award-info":[{"award-number":["81970176"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972596"],"award-info":[{"award-number":["81972596"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"Singapore National Medical Research Council","doi-asserted-by":"crossref","award":["NMRC-TCR-12Dec005"],"award-info":[{"award-number":["NMRC-TCR-12Dec005"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Cancer Centre Research Fund","award":["NCCRF-OACPCCS-YR2015-AUG2"],"award-info":[{"award-number":["NCCRF-OACPCCS-YR2015-AUG2"]}]},{"name":"Neighborhood Funders Group Fund","award":["NMRC\/TA\/0051\/2016"],"award-info":[{"award-number":["NMRC\/TA\/0051\/2016"]}]},{"DOI":"10.13039\/100018059","name":"Tanoto Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018059","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ling Foundation"},{"name":"New Century Foundation"},{"DOI":"10.13039\/100012541","name":"Guangdong Innovative and Entrepreneurial Research Team Program","doi-asserted-by":"publisher","award":["2016ZT06S638"],"award-info":[{"award-number":["2016ZT06S638"]}],"id":[{"id":"10.13039\/100012541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Sci-Tech Project Foundation of Guangzhou City","doi-asserted-by":"crossref","award":["201707020039"],"award-info":[{"award-number":["201707020039"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Natural killer\/T-cell lymphoma (NKTL) is a rare type of aggressive and heterogeneous non-Hodgkin's lymphoma (NHL) with a poor prognosis and limited therapeutic options. Therefore, there is an urgent need to exploit potential novel therapeutic targets for the treatment of NKTL. Histone deacetylase (HDAC) inhibitor chidamide was recently approved for treating relapsed\/refractory peripheral T-cell lymphoma (PTCL) patients. However, its therapeutic efficacy in NKTL remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a phase II clinical trial to evaluate the efficacy of chidamide in 28 relapsed\/refractory NKTL patients. Integrative transcriptomic, chromatin profiling analysis and functional studies were performed to identify potential predictive biomarkers and unravel the mechanisms of resistance to chidamide. Immunohistochemistry (IHC) was used to validate the predictive biomarkers in tumors from the clinical trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We demonstrated that chidamide is effective in treating relapsed\/refractory NKTL patients, achieving an overall response and complete response rate of 39 and 18%, respectively. In vitro studies showed that hyperactivity of JAK-STAT signaling in NKTL cell lines was associated with the resistance to chidamide. Mechanistically, our results revealed that aberrant JAK-STAT signaling remodels the chromatin and confers resistance to chidamide. Subsequently, inhibition of JAK-STAT activity could overcome resistance to chidamide by reprogramming the chromatin from a resistant to sensitive state, leading to synergistic anti-tumor effect in vitro and in vivo. More importantly, our clinical data demonstrated that combinatorial therapy with chidamide and JAK inhibitor ruxolitinib is effective against chidamide-resistant NKTL. In addition, we identified TNFRSF8 (CD30), a downstream target of the JAK-STAT pathway, as a potential biomarker that could predict NKTL sensitivity to chidamide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study suggests that chidamide, in combination with JAK-STAT inhibitors, can be a novel targeted therapy in the standard of care for NKTL.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration<\/jats:italic>\n                      : ClinicalTrials.gov, NCT02878278. Registered 25 August 2016,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02878278\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02878278<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13148-023-01436-6","type":"journal-article","created":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T22:02:57Z","timestamp":1675634577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK\/T-cell lymphoma to chidamide"],"prefix":"10.1186","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct02878278","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jinghong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiang","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosai","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyong","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Han","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason Yongsheng","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl Ming Zhe","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingquan","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelila Xin Ye","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burton Kuan Hui","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane Wan Lu","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dachuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shini","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil Ajit","family":"Saraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas Francis","family":"Grigoropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxin","family":"Bei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiebang","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon Thye","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin Tean","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choon Kiat","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"issue":"25","key":"1436_CR1","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1436_CR2","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1097\/PAS.0b013e31821ec4b5","volume":"35","author":"G Gualco","year":"2011","unstructured":"Gualco G, Domeny-Duarte P, Chioato L, Barber G, Natkunam Y, Bacchi CE. Clinicopathologic and molecular features of 122 Brazilian cases of nodal and extranodal NK\/T-cell lymphoma, nasal type, with EBV subtyping analysis. Am J Surg Pathol. 2011;35(8):1195\u2013203.","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"1436_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/2211-5463.12027","volume":"6","author":"J Alles","year":"2016","unstructured":"Alles J, Menegatti J, Motsch N, Hart M, Eichner N, Reinhardt R, et al. miRNA expression profiling of Epstein-Barr virus-associated NKTL cell lines by Illumina deep sequencing. FEBS Open Bio. 2016;6(4):251\u201363.","journal-title":"FEBS Open Bio"},{"issue":"2","key":"1436_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/hon.847","volume":"26","author":"R Suzuki","year":"2008","unstructured":"Suzuki R, Takeuchi K, Ohshima K, Nakamura S. Extranodal NK\/T-cell lymphoma: diagnosis and treatment cues. Hematol Oncol. 2008;26(2):66\u201372.","journal-title":"Hematol Oncol"},{"issue":"1","key":"1436_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1365-2141.2009.07802.x","volume":"147","author":"R Liang","year":"2009","unstructured":"Liang R. Advances in the management and monitoring of extranodal NK\/T-cell lymphoma, nasal type. Br J Haematol. 2009;147(1):13\u201321.","journal-title":"Br J Haematol"},{"issue":"5","key":"1436_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.clml.2014.12.014","volume":"15","author":"RK Chaudhary","year":"2015","unstructured":"Chaudhary RK, Bhatt VR, Vose JM. Management of extranodal natural killer\/t-cell lymphoma, nasal type. Clin Lymphoma Myeloma Leuk. 2015;15(5):245\u201352.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"1436_CR7","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","volume":"117","author":"A Jaccard","year":"2011","unstructured":"Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma, a phase 2 study. Blood. 2011;117(6):1834\u20139.","journal-title":"Blood"},{"issue":"15","key":"1436_CR8","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","volume":"120","author":"YL Kwong","year":"2012","unstructured":"Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, et al. SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012;120(15):2973\u201380.","journal-title":"Blood"},{"issue":"1","key":"1436_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrg2485","volume":"10","author":"M Haberland","year":"2009","unstructured":"Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009;10(1):32\u201342.","journal-title":"Nat Rev Genet"},{"issue":"9","key":"1436_CR10","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ng.3358","volume":"47","author":"L Jiang","year":"2015","unstructured":"Jiang L, Gu ZH, Yan ZX, Zhao X, Xie YY, Zhang ZG, et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer\/T-cell lymphoma. Nat Genet. 2015;47(9):1061\u20136.","journal-title":"Nat Genet"},{"issue":"19","key":"1436_CR11","doi-asserted-by":"publisher","first-page":"17764","DOI":"10.18632\/oncotarget.3776","volume":"6","author":"S Lee","year":"2015","unstructured":"Lee S, Park HY, Kang SY, Kim SJ, Hwang J, Lee S, et al. Genetic alterations of JAK\/STAT cascade and histone modification in extranodal NK\/T-cell lymphoma nasal type. Oncotarget. 2015;6(19):17764\u201376.","journal-title":"Oncotarget"},{"issue":"9","key":"1436_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.molmed.2007.07.003","volume":"13","author":"GG Wang","year":"2007","unstructured":"Wang GG, Allis CD, Chi P. Chromatin remodeling and cancer, Part I: covalent histone modifications. Trends Mol Med. 2007;13(9):363\u201372.","journal-title":"Trends Mol Med"},{"issue":"6","key":"1436_CR13","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1080\/10428194.2016.1247956","volume":"58","author":"AJ Moskowitz","year":"2017","unstructured":"Moskowitz AJ, Horwitz SM. Targeting histone deacetylases in T-cell lymphoma. Leuk Lymphoma. 2017;58(6):1306\u201319.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"1436_CR14","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","volume":"12","author":"BS Mann","year":"2007","unstructured":"Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12(10):1247\u201352.","journal-title":"Oncologist"},{"issue":"29","key":"1436_CR15","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","volume":"28","author":"SJ Whittaker","year":"2010","unstructured":"Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(29):4485\u201391.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1436_CR16","first-page":"411","volume":"18","author":"XG Yuan","year":"2019","unstructured":"Yuan XG, Huang YR, Yu T, Jiang HW, Xu Y, Zhao XY. Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner. Oncol Lett. 2019;18(1):411\u20139.","journal-title":"Oncol Lett"},{"issue":"1","key":"1436_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41419-019-2210-0","volume":"11","author":"XW Guan","year":"2020","unstructured":"Guan XW, Wang HQ, Ban WW, Chang Z, Chen HZ, Jia L, et al. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20. Cell Death Dis. 2020;11(1):20.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1436_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","volume":"10","author":"Y Shi","year":"2017","unstructured":"Shi Y, Jia B, Xu W, Li W, Liu T, Liu P, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol. 2017;10(1):69.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"1436_CR19","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440\u20136.","journal-title":"Cancer Res"},{"issue":"1","key":"1436_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ccell.2016.12.003","volume":"31","author":"J Paul","year":"2017","unstructured":"Paul J, Soujon M, Wengner AM, Zitzmann-Kolbe S, Sturz A, Haike K, et al. Simultaneous inhibition of PI3Kdelta and PI3Kalpha induces ABC-DLBCL regression by blocking BCR-dependent and -independent activation of NF-kappaB and AKT. Cancer Cell. 2017;31(1):64\u201378.","journal-title":"Cancer Cell"},{"issue":"11","key":"1436_CR21","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1182\/blood-2018-01-829424","volume":"132","author":"TL Song","year":"2018","unstructured":"Song TL, Nairismagi ML, Laurensia Y, Lim JQ, Tan J, Li ZM, et al. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer\/T-cell lymphoma. Blood. 2018;132(11):1146\u201358.","journal-title":"Blood"},{"issue":"11","key":"1436_CR22","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1158\/2159-8290.CD-17-0375","volume":"7","author":"X Yao","year":"2017","unstructured":"Yao X, Tan J, Lim KJ, Koh J, Ooi WF, Li Z, et al. VHL Deficiency drives enhancer activation of oncogenes in clear cell renal cell carcinoma. Cancer Discov. 2017;7(11):1284\u2013305.","journal-title":"Cancer Discov"},{"issue":"2","key":"1436_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.stem.2016.11.003","volume":"20","author":"BB Liau","year":"2017","unstructured":"Liau BB, Sievers C, Donohue LK, Gillespie SM, Flavahan WA, Miller TE, et al. Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance. Cell Stem Cell. 2017;20(2):233-46.e7.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"1436_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1158\/2159-8290.CD-17-0461","volume":"8","author":"M Rusan","year":"2018","unstructured":"Rusan M, Li K, Li Y, Christensen CL, Abraham BJ, Kwiatkowski N, et al. Suppression of adaptive responses to targeted cancer therapy by transcriptional repression. Cancer Discov. 2018;8(1):59\u201373.","journal-title":"Cancer Discov"},{"issue":"4","key":"1436_CR25","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.molcel.2010.05.004","volume":"38","author":"S Heinz","year":"2010","unstructured":"Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010;38(4):576\u201389.","journal-title":"Mol Cell"},{"issue":"5","key":"1436_CR26","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/s41375-017-0004-x","volume":"32","author":"M Nairismagi","year":"2018","unstructured":"Nairismagi M, Gerritsen ME, Li ZM, Wijaya GC, Chia B, Laurensia Y, et al. Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer\/T-cell lymphoma. Leukemia. 2018;32(5):1147\u201356.","journal-title":"Leukemia"},{"issue":"2","key":"1436_CR27","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","volume":"7","author":"DS Shin","year":"2017","unstructured":"Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, et al. Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations. Cancer Discov. 2017;7(2):188\u2013201.","journal-title":"Cancer Discov"},{"issue":"9","key":"1436_CR28","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819\u201329.","journal-title":"N Engl J Med"},{"issue":"2","key":"1436_CR29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1158\/2159-8290.CD-16-1439","volume":"7","author":"A Marabelle","year":"2017","unstructured":"Marabelle A, Aspeslagh S, Postel-Vinay S, Soria JC. JAK mutations as escape mechanisms to Anti-PD-1 therapy. Cancer Discov. 2017;7(2):128\u201330.","journal-title":"Cancer Discov"},{"issue":"6377","key":"1436_CR30","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1126\/science.aao1710","volume":"359","author":"D Pan","year":"2018","unstructured":"Pan D, Kobayashi A, Jiang P, Ferrari DAL, Tay RE, Luoma AM, et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science. 2018;359(6377):770\u20135.","journal-title":"Science"},{"issue":"4","key":"1436_CR31","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","volume":"69","author":"ZQ Ning","year":"2012","unstructured":"Ning ZQ, Li ZB, Newman MJ, Shan S, Wang XH, Pan DS, et al. Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 2012;69(4):901\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"1436_CR32","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1517\/13543784.2016.1164140","volume":"25","author":"S Apuri","year":"2016","unstructured":"Apuri S, Sokol L. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin\u2019s lymphoma. Expert Opin Investig Drugs. 2016;25(6):687\u201396.","journal-title":"Expert Opin Investig Drugs"},{"issue":"10","key":"1436_CR33","doi-asserted-by":"publisher","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","volume":"6","author":"Y Li","year":"2016","unstructured":"Li Y, Seto E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 2016;6(10):a026831.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"7265","key":"1436_CR34","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/nature08448","volume":"461","author":"MA Dawson","year":"2009","unstructured":"Dawson MA, Bannister AJ, Gottgens B, Foster SD, Bartke T, Green AR, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature. 2009;461(7265):819\u201322.","journal-title":"Nature"},{"issue":"7","key":"1436_CR35","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/emboj.2009.30","volume":"28","author":"JM Wojciak","year":"2009","unstructured":"Wojciak JM, Martinez-Yamout MA, Dyson HJ, Wright PE. Structural basis for recruitment of CBP\/p300 coactivators by STAT1 and STAT2 transactivation domains. EMBO J. 2009;28(7):948\u201358.","journal-title":"EMBO J"},{"issue":"5","key":"1436_CR36","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.immuni.2010.05.003","volume":"32","author":"L Durant","year":"2010","unstructured":"Durant L, Watford WT, Ramos HL, Laurence A, Vahedi G, Wei L, et al. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity. 2010;32(5):605\u201315.","journal-title":"Immunity"},{"issue":"19","key":"1436_CR37","doi-asserted-by":"publisher","first-page":"6948","DOI":"10.1073\/pnas.0501959102","volume":"102","author":"Q Zhang","year":"2005","unstructured":"Zhang Q, Wang HY, Marzec M, Raghunath PN, Nagasawa T, Wasik MA. STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci U S A. 2005;102(19):6948\u201353.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"1436_CR38","doi-asserted-by":"publisher","first-page":"7765","DOI":"10.1073\/pnas.1205132109","volume":"109","author":"H Lee","year":"2012","unstructured":"Lee H, Zhang P, Herrmann A, Yang C, Xin H, Wang Z, et al. Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc Natl Acad Sci U S A. 2012;109(20):7765\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1436_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","volume":"33","author":"M Kleppe","year":"2018","unstructured":"Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, et al. Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell. 2018;33(1):29-43.e7.","journal-title":"Cancer Cell"},{"issue":"12","key":"1436_CR40","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1158\/0008-5472.CAN-17-3146","volume":"78","author":"MR Yun","year":"2018","unstructured":"Yun MR, Lim SM, Kim SK, Choi HM, Pyo KH, Kim SK, et al. Enhancer remodeling and MicroRNA alterations are associated with acquired resistance to ALK inhibitors. Cancer Res. 2018;78(12):3350\u201362.","journal-title":"Cancer Res"},{"issue":"4","key":"1436_CR41","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/ng.2913","volume":"46","author":"B Knoechel","year":"2014","unstructured":"Knoechel B, Roderick JE, Williamson KE, Zhu J, Lohr JG, Cotton MJ, et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat Genet. 2014;46(4):364\u201370.","journal-title":"Nat Genet"},{"issue":"3","key":"1436_CR42","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1158\/2159-8290.CD-16-0653","volume":"7","author":"JS Zawistowski","year":"2017","unstructured":"Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, et al. Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex. Cancer Discov. 2017;7(3):302\u201311.","journal-title":"Cancer Discov"},{"issue":"8","key":"1436_CR43","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","volume":"98","author":"E Sabattini","year":"2013","unstructured":"Sabattini E, Pizzi M, Tabanelli V, Baldin P, Sacchetti CS, Agostinelli C, et al. CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013;98(8):e81\u20132.","journal-title":"Haematologica"},{"issue":"1","key":"1436_CR44","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/hon.2482","volume":"36","author":"K Kawamoto","year":"2018","unstructured":"Kawamoto K, Miyoshi H, Suzuki T, Sasaki Y, Yamada K, Yanagida E, et al. Frequent expression of CD30 in extranodal NK\/T-cell lymphoma: potential therapeutic target for anti-CD30 antibody-based therapy. Hematol Oncol. 2018;36(1):166\u201373.","journal-title":"Hematol Oncol"},{"issue":"6","key":"1436_CR45","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.3109\/10428194.2014.974048","volume":"56","author":"WY Kim","year":"2015","unstructured":"Kim WY, Nam SJ, Kim S, Kim TM, Heo DS, Kim CW, et al. Prognostic implications of CD30 expression in extranodal natural killer\/T-cell lymphoma according to treatment modalities. Leuk Lymphoma. 2015;56(6):1778\u201386.","journal-title":"Leuk Lymphoma"},{"issue":"10168","key":"1436_CR46","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229\u201340.","journal-title":"Lancet"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-023-01436-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-023-01436-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-023-01436-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T11:03:22Z","timestamp":1675767802000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-023-01436-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1436"],"URL":"https:\/\/doi.org\/10.1186\/s13148-023-01436-6","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,6]]},"assertion":[{"value":"3 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review board of SYSUCC in accordance with the Declaration of Helsinki, and applicable regulations according to Good Clinical Practice guidelines. Written informed consent was obtained from all patients before enrollment in the trial. This trial was registered at ClinicalTrials.gov, number NCT02878278. Research protocols for tumor collection and analysis were approved by the ethical committees of the SYSUCC. In vivo studies were conducted in compliance with animal protocols approved by the SingHealth Institutional Animal Care and Use Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have agreed to publish this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}